"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03265808","Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.","Alaunus","Active, not recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo","Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI","Ihsan Salloum|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170674|1R01AA024933-01A1","March 18, 2018","October 23, 2022","April 2025","August 29, 2017",,"February 28, 2022","University of Texas Rio Grande Valley School of Medicine, Harlingen, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03265808"
2,"NCT02065245","AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery","CRATUS","Completed","Has Results","Frailty","Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo|Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)","Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels","Longeveron Inc.|The Emmes Company, LLC","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20130646","March 3, 2014","October 2, 2019","October 2, 2020","February 17, 2014","April 27, 2021","July 14, 2021","ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02065245/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02065245"
3,"NCT01087996","The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)",,"Completed","Has Results","Stem Cell Transplantation","Biological: Auto-hMSCs|Biological: Allo-hMSCs","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849","March 2010","April 2011","October 2012","March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087996"
4,"NCT02886884","Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects","ACESO","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells","Number of Treatment Emergent Serious Adverse Events (TE-SAEs)|EPC-CFU Levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels|Tumor Necrosis Factor (TNF) Alpha Levels","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160686|1R01HL134558-01","October 20, 2017","August 26, 2019","September 3, 2020","September 1, 2016","May 11, 2022","May 11, 2022","University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02886884/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02886884"
5,"NCT02013674","The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)","Trident","Completed","Has Results","Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction","Biological: Allogeneic hMSCs","Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB)","Joshua M Hare|The Emmes Company, LLC|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120660","February 13, 2014","March 2, 2017","September 18, 2017","December 17, 2013","February 5, 2020","February 11, 2020","ISCI / University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02013674/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02013674"
6,"NCT04476901","Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","DCMII","Recruiting","No Results Available","Non-ischemic Dilated Cardiomyopathy","Biological: allogeneic human mesenchymal stem cells (hMSCs)|Other: Placebo","Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs","Joshua M Hare|United States Department of Defense|The University of Texas Health Science Center, Houston|University of Miami","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","136","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200566|CDMRP-PR191597|20-02-134","May 7, 2021","December 2024","December 2024","July 20, 2020",,"September 29, 2022","Stanford University, Stanford, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Texas Heart Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04476901"
7,"NCT01392625","PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)","PoseidonDCM","Completed","Has Results","Non-ischemic Dilated Cardiomyopathy","Biological: Autologous hMSCs|Biological: Allogeneic hMSCs","Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20100968|1R01HL110737-01","May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01392625"
